Physician profile
Dania E Mancha
NPI 1730811837
$378.16
in general payments reported to CMS, 2019-2025
14 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $25.30 · 2023: $110 · 2024: $142 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $335 · Entertainment: $18.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $334.58 |
| Entertainment | $18.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $97.91 | 2023-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $38.50 | 2023-2024 | |
| Exact Sciences Corporation | $37.51 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.89 | 2022-2024 | Jardiance |
| Lilly USA, LLC | $27.87 | 2023 | Mounjaro |
| Amgen INC. | $19.18 | 2024 | Otezla, Repatha |
| Collegium Pharmaceutical, INC. | $18.52 | 2023 | Xtampza |
| Inspire Medical Systems, INC. | $18.31 | 2025 | Inspire |
| Optos, INC. | $18.28 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Dexcom, INC. | $17.49 | 2025 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $15.13 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.55 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $12.84 | 2023 | Breztri |
| Sanofi-Aventis U.S. LLC | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dania Mancha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.